

[AAAAI Foundation and Allen P. Kaplan, MD FAAAAI Lectureship: Creating Knowledge for Our Future \(4th year\)](#)

1601 Presidential Plenary: Paradigm Shifts in Drug Allergy
Friday, February 24, 2023
Convention Center, Lobby Level, Hall 2, 1:45 pm – 3:15 pm
Lecturer: Elizabeth Phillips, MD FAAAAI FIDSA
Advances in Diagnosis and Management of SCAR

AAAAI Foundation and Allen P. Kaplan, MD FAAAAI Lectureship: Creating Knowledge for Our Future will be presented by Elizabeth Phillips, MD FAAAAI FIDSA on Friday, February 24th during the Presidential Plenary: Paradigm Shifts in Drug Allergy (1601) in Convention Center, Lobby Level, Hall 2, 1:45 pm – 3:15 pm (presentation at 2:20 pm)

Allen P. Kaplan, MD FAAAAI



The AAAAI Foundation is pleased to honor the life work of Dr. Allen P. Kaplan with the creation of the Allen P. Kaplan, MD FAAAAI Lectureship: Creating Knowledge for Our Future. Throughout his long career, Dr. Kaplan has made an important mark on the Allergy/Immunology specialty through his work as a physician scientist and as a beloved mentor to many in our field.

Dr. Kaplan is clinical professor of medicine at the Medical University of South Carolina (MUSC) in Charleston, South Carolina and has been associated with the Division of Pulmonary Medicine and Allergy and Immunology for the past 21 years. He is a graduate of Columbia University and Downstate Medical School in Brooklyn, New York, and completed his specialty training in allergy and clinical immunology at Harvard Medical School, and his rheumatology training at the National Institutes of Health. Dr. Kaplan served as the head of allergic diseases at the National Institutes of Health, and then chairman of the Department of Medicine and director of the Division of Allergy, Rheumatology and Clinical Immunology at the State University of New York at Stony Brook. Dr. Kaplan has contributed significantly to the future of his beloved specialty through the countless fellows and trainees who have learned under his tutelage at Stony Brook as well as pulmonologists at MUSC.

Dr. Kaplan has served at the highest levels of leadership within the specialty. He held the office of President of the American Academy of Allergy Asthma & Immunology in 1989, served as the President of the Clinical Immunology Society in 1990 and

became the second American to lead the World Allergy Organization during his time as President from 2000 to 2003.

Dr. Kaplan has authored more than 350 articles, monographs, and editorials, and he edited the textbook titled *Allergy*, which has been utilized in training programs throughout the world. In addition, he coedited the textbook titled *Urticaria and Angioedema* as well as a two-volume textbook titled *Allergy and Allergic Diseases*. Dr. Kaplan's research interests focus on inflammatory mechanisms of allergic disease and he is a world-renowned authority on the mechanisms and treatment of urticaria and angioedema.

Elizabeth Phillips, MD FAAAAI FIDSA



Dr. Elizabeth Phillips is Professor of Medicine, Dermatology, Pharmacology and Pathology, Microbiology and Immunology at Vanderbilt University Medical Center and Vanderbilt University Medical School. She is the John A. Oates Chair in Clinical Research and Director of Personalized Immunology in the Center for Drug Safety and Immunology. She is a physician scientist clinically trained in Infectious diseases, immunology and clinical pharmacology who has established new clinical and research programs in drug hypersensitivity, pharmacogenomics and personalized immunology across different healthcare systems. She has published over 300 peer reviewed articles related to hypersensitivity reactions to drugs and vaccines. She is recognized for elucidating mechanisms and genetic determinants of drug hypersensitivity which have transformed research, clinical practice and training in the United States and Internationally. She is PI on an NIH funded clinical trial which will be the first randomized double-blinded controlled trial to study the optimal management and mechanisms of SJS/TEN. Amongst her greatest translational accomplishments between 2002-2008 she led the development of the HLA-B*57:01 genetic predictor for abacavir hypersensitivity from its discovery through implementation. Her discovery through translation pipeline continues to pioneer strategies to prevent, diagnose and mitigate harm from true drug hypersensitivity and she is applying novel technologies to understand the single cell pathology of drug hypersensitivity at the site of tissue damage leading to identification of new therapeutic targets. She has also led development of clinical practice and guidance dedicated to the care of drug hypersensitivity patients and her clinics have acted as a model for others within the US and internationally. Her efforts have transformed care across multiple disciplines and she is a true community leader and advocate for those with severe cutaneous adverse drug reactions, working alongside patients and foundations to advance education, awareness and science of drug hypersensitivity. She was the

founder and chair of NIH-funded SJS/TEN meetings in 2017, 2019 and 2021 and the Inaugural DRESS syndrome 2022 meeting and planned SJS/TEN 2023 meetings which actively unite the science and lay communities.